Payment overview · 2025
General Payments
$690.24
33 reported records · 12 companies
Healthcare provider profile · identity verified
John A Friedline, MD
Allopathic & Osteopathic Physicians|Family Medicine · EL CENTRO, CA · NPI 1447311261
Verified facts
What the public records show
CMS Open Payments records show John A Friedline, MD received $690.24 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.36 | 19.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.12 | 14.8% | 5 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $100.05 | 14.5% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $94.11 | 13.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.28 | 12.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.53 | 8.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.18 | 3.9% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.21 | 3.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.78 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.87 | 2.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.44 | 2.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $9.31 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $690.24 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $100.47 | 4 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $100.05 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $94.11 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $86.02 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.87 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $9.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 152 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 22 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
152 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 148 |
| Metformin Hcl | Metformin Hcl | 385 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 355 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 98 |
| Losartan Potassium | Losartan Potassium | 312 | 104 |
| Omeprazole | Omeprazole | 309 | 124 |
| Gabapentin | Gabapentin | 273 | 106 |
| Tramadol Hcl | Tramadol Hcl | 269 | 97 |
| Lisinopril | Lisinopril | 200 | 70 |
| Alendronate Sodium | Alendronate Sodium | 197 | 64 |
| Quetiapine Fumarate | Quetiapine Fumarate | 188 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 66 |
| Celecoxib | Celecoxib | 163 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 75 |
| Ibuprofen | Ibuprofen | 159 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 56 |
| Mounjaro | Tirzepatide | 152 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 149 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 56 |
| Dexamethasone | Dexamethasone | 128 | 93 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 128 | 28 |
| Meloxicam | Meloxicam | 124 | 59 |
| Glimepiride | Glimepiride | 101 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 39 |
| Ozempic | Semaglutide | 99 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 36 |
| Cefdinir | Cefdinir | 96 | 75 |
| Montelukast Sodium | Montelukast Sodium | 96 | 40 |
| Furosemide | Furosemide | 94 | 42 |
| Baclofen | Baclofen | 90 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 21 |
| Rybelsus | Semaglutide | 80 | 27 |
| Carvedilol | Carvedilol | 79 | 35 |
| Pentoxifylline | Pentoxifylline | 79 | 37 |
| Donepezil Hcl | Donepezil Hcl | 78 | 26 |
| Terbinafine Hcl | Terbinafine Hcl | 78 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 28 |
| Leflunomide | Leflunomide | 75 | 32 |
| Alprazolam | Alprazolam | 72 | 27 |
| Azithromycin | Azithromycin | 71 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 25 |
| Eliquis | Apixaban | 71 | 25 |
| Jardiance | Empagliflozin | 71 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 58 |
| Trazodone Hcl | Trazodone Hcl | 68 | 26 |
| Linzess | Linaclotide | 66 | 31 |
| Allopurinol | Allopurinol | 65 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 21 |
| Ezetimibe | Ezetimibe | 63 | 27 |
| Lorazepam | Lorazepam | 63 | 25 |
| Pregabalin | Pregabalin | 63 | 24 |
| Buspirone Hcl | Buspirone Hcl | 62 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 17 |
| Famotidine | Famotidine | 62 | 20 |
| Meclizine Hcl | Meclizine Hcl | 61 | 34 |
| Potassium Chloride | Potassium Chloride | 57 | 18 |
| Januvia | Sitagliptin Phosphate | 56 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 18 |
| Simvastatin | Simvastatin | 55 | 25 |
| Sertraline Hcl | Sertraline Hcl | 54 | 18 |
| Clonazepam | Clonazepam | 52 | 14 |
| Farxiga | Dapagliflozin Propanediol | 52 | 22 |
| Naproxen | Naproxen | 52 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 26 |
| Fenofibrate | Fenofibrate,micronized | 48 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 19 |
| Finasteride | Finasteride | 45 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 14 |
| Trulicity | Dulaglutide | 45 | 12 |
| Estradiol | Estradiol | 43 | 21 |
| Enalapril Maleate | Enalapril Maleate | 39 | 11 |
| Fenofibrate | Fenofibrate | 39 | 14 |
| Hydrocortisone | Hydrocortisone | 39 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 14 |
| Cephalexin | Cephalexin | 37 | 36 |
| Benazepril Hcl | Benazepril Hcl | 36 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Methimazole | Methimazole | 34 | 16 |
| Xarelto | Rivaroxaban | 34 | 15 |
| Fluconazole | Fluconazole | 33 | 23 |
| Entresto | Sacubitril/Valsartan | 32 | 12 |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | 13 |
| Lidocaine | Lidocaine | 31 | suppressed |
| Ursodiol | Ursodiol | 31 | 13 |
| Amoxicillin | Amoxicillin | 30 | 27 |
| Lubiprostone | Lubiprostone | 30 | 15 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Prednisone | Prednisone | 30 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 11 |
| Lansoprazole | Lansoprazole | 28 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Kerendia | Finerenone | 26 | 12 |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Roflumilast | Roflumilast | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 11 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Glipizide | Glipizide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | 15 |
| Tobramycin | Tobramycin | 20 | 13 |
| Valsartan | Valsartan | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 12 |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Testosterone | Testosterone | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $690.24 · 33 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, CeQur Simplicity, Cologuard Collection Kit, FARXIGA, GIVLAARI, ISTURISA, JARDIANCE, KISUNLA, Kerendia, Korlym, MOUNJARO, SHINGRIX, TRELEGY ELLIPTA, VERQUVO, Veozah, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error